Aug 25 — Novo Nordisk Chief Executive Lars Fruergaard Jorgensen said today he was confident Catalent would resolves its problems making Novo’s hugely-popular weight-loss drug Wegovy as the company scrambles to boost output to meet soaring demand.
“I am confident in that,” Jorgensen said at a Reuters Newsmaker event, when asked about the issues Catalent has had.
Reuters reported in July that Catalent’s factory in Brussels that fills Wegovy injection pens had repeatedly breached US sterile-safety rules in recent years and staff had failed to perform required quality checks.
The Danish drugmaker hopes to have a third external facility filling and finishing the injection pens by 2024, Jorgensen said. The company has previously said it expected to add the third line in the second half of this year.
Even so, it will be “quite some years” before the company can satisfy the whole market for Wegovy, he said. — Reuters
